Cencora, Inc. (NYSE:COR) Shares Purchased by Lindbrook Capital LLC

Lindbrook Capital LLC increased its holdings in shares of Cencora, Inc. (NYSE:COR) by 24.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 661 shares of the company’s stock after acquiring an additional 130 shares during the quarter. Lindbrook Capital LLC’s holdings in Cencora were worth $149,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Swedbank AB grew its position in Cencora by 2.3% in the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock worth $313,863,000 after purchasing an additional 31,104 shares during the last quarter. Harbor Capital Advisors Inc. bought a new position in Cencora in the 3rd quarter worth about $62,000. Catalina Capital Group LLC bought a new position in Cencora in the 3rd quarter worth about $215,000. Concurrent Investment Advisors LLC grew its position in Cencora by 12.1% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 7,697 shares of the company’s stock worth $1,732,000 after purchasing an additional 832 shares during the last quarter. Finally, Graypoint LLC grew its position in Cencora by 7.8% in the 3rd quarter. Graypoint LLC now owns 1,171 shares of the company’s stock worth $264,000 after purchasing an additional 85 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analysts Set New Price Targets

COR has been the subject of several recent analyst reports. StockNews.com cut shares of Cencora from a “buy” rating to a “hold” rating in a report on Tuesday. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Evercore ISI increased their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Wells Fargo & Company increased their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a report on Wednesday, January 29th. Finally, Mizuho initiated coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective for the company. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and a consensus price target of $277.90.

Cencora Stock Up 0.3 %

Shares of NYSE:COR opened at $254.54 on Friday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The company has a market cap of $49.36 billion, a PE ratio of 36.21, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $262.26. The firm has a 50 day simple moving average of $244.34 and a 200 day simple moving average of $238.40.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.86%. Cencora’s payout ratio is 31.29%.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 4,970 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total value of $1,267,350.00. Following the completion of the sale, the chief executive officer now owns 51,070 shares in the company, valued at $13,022,850. This represents a 8.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,648 shares of company stock worth $2,862,342 in the last quarter. 10.80% of the stock is currently owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.